Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation

Transplantation

Volumn 74, Issue 8, 2002, Pages 1119-1124

  Andreone, Pietro ^a   Biselli, Maurizio ^a   Gramenzi, Annagiulia ^a   Cursaro, Carmela ^a   Morelli, Maria C ^a   Sama, Claudia ^a   Lorenzini, Stefania ^a   Spinucci, Giulio ^a   Porzio, Federica ^a   Felline, Francesco ^a   Di Giammarino, Loriana ^a   Bernardi, Mauro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; LAMIVUDINE; SERUM ALBUMIN; VIRUS DNA;

ADULT; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; CHILD PUGH SCORING; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL EXAMINATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER DISEASE; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROBABILITY; PROTHROMBIN TIME; RECURRENT DISEASE; SCORING SYSTEM; SURVIVAL; VIRUS DETECTION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN;

EID: 0037184319     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200210270-00011     Document Type: Article

References (26)

1. Dianzani F. Chronic hepatitis B, biological basis for new therapeutic strategies. J Biol Regul Homeost Agents 1999; 13: 71.
2. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: Serological and clinical implications. J Hepatol 1992; 14: 104.
3. Todo S, DeMetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619.
4. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alpha in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908.
5. Marcellin P, Giuily N, Loriot MA, et al. Prolonged interferon-alpha therapy of hepatitis B virus-related decompensated cirrhosis. J Viral Hepat 1997; 4 (suppl 1): 21.
6. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256.
7. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61.
8. Van Thiel DH, Friedlander L, Kania RJ, et al. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepato-Gastroenterology 1997; 44: 808.
9. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62: 1456.
10. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207.
11. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301.
12. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308.
13. Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transpl 2000; 6: 715.
14. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424.
15. Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411.
16. Keeffe EB. Summary of guidelines on organ allocation and patient listing for liver transplantation. Liver Transplant Surg 1998; 4 (suppl 1): S108.
17. Fontana RJ, Keeffe EB, Soldevilla C, et al. Is lamivudine beneficial in HBsAg + patients awaiting liver transplantation? Experience in 182 North American patients [abstract]. Transplantation 1999; 67: S16.
18. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudinein patients with hepatitis B e antigen-negative/hepatitis B virus-DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889.
19. Perrillo RP. Acute flare in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009.
20. Laras A, Koskinas J, Avgidis K, et al. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepatitis 1998; 5: 241.
21. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122.
22. Cuervas-Mons V, Millan I, Gavaler JS, et al. Prognostic value of preoperatively obtained clinical and laboratory data in predicting survival following orthotopic liver transplantation. Hepatology 1986; 6: 922.
23. Fontana RJ, Lok ASF. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? J Hepatol 2000; 33: 329.
24. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20.
25. Liaw Y, Chien R, Yeh C, Tsai SL, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567.
26. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129.